Testing DNA-based blood tests in early pancreatic cancer
Part of Cancer clinical trials.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have (or are suspected to have) pancreatic ductal adenocarcinoma (PDAC) that is stage I, II, or III
- You are scheduled for pancreatic surgery to remove the tumor (with or without chemotherapy before surgery)
- You must be able to get a follow-up CT scan about 4 months after surgery
- If you already had surgery: your surgeon plans curative removal (R0 or R1) and CT at ~4 months shows no local return or spread to other organs
- You have not had another cancer diagnosed within the last 3 years (except certain skin cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial is studying a blood test that looks for tumor DNA (ctDNA) to see if it can help predict how well treatment is working in people with pancreatic cancer that hasn't spread. It is for patients getting chemotherapy before possible surgery.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
Hear when a new Resectable Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.